EcoDrugPlus

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSMLUG00000013928
Gene Symbol: F2RL3
2 Cross references
197 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSMLUG00000015848
Gene Symbol: FXYD2
1 Cross references
74 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMLUG00000007330
Gene Symbol: FYN
2 Cross references
261 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSMLUG00000016344
Gene Symbol: GPR119
2 Cross references
174 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSMLUG00000012933
Gene Symbol: GPR84
2 Cross references
124 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMLUG00000008355
Gene Symbol: HCK
2 Cross references
205 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSMLUG00000015811
Gene Symbol: ITK
4 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSMLUG00000007723
Gene Symbol: JAK1
4 Cross references
236 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSMLUG00000012756
Gene Symbol: JAK2
2 Cross references
265 Possible Orthologues:

Janus Kinase 3

Ensembl ID : ENSMLUG00000006664
Gene Symbol: JAK3
2 Cross references
103 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSMLUG00000002438
Gene Symbol: KIT
2 Cross references
265 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSMLUG00000015948
Gene Symbol: KRAS
2 Cross references
201 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).